Eligibility NCT00216879 Psoriasis Inclusion Criteria Exclusion Criteria PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation Yes
No
UVB therapy anywhere on the patient within 14 days prior to randomisation Yes
No
Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton Yes
No
Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation Yes
No
Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton Yes
No
Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation Yes
No
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study Yes
No
Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis Yes
No
Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin Yes
No
Known or suspected severe renal insufficiency or severe hepatic disorders Yes
No
Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia Yes
No
Trial subjects should be using an adequate method of contraception Yes
No
Medical Concepts 
